tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Alcon (ALC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Boston Scientific (BSXResearch Report) and Alcon (ALCResearch Report) with bullish sentiments.

Boston Scientific (BSX)

BTIG analyst Marie Thibault reiterated a Buy rating on Boston Scientific today and set a price target of $52.00. The company’s shares closed last Monday at $39.89.

According to TipRanks.com, Thibault is a 4-star analyst with an average return of 8.8% and a 28.0% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies.

Boston Scientific has an analyst consensus of Moderate Buy, with a price target consensus of $49.85, representing a 25.8% upside. In a report issued on May 16, Morgan Stanley also maintained a Buy rating on the stock with a $51.00 price target.

See the top stocks recommended by analysts >>

Alcon (ALC)

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Alcon, with a price target of $85.00. The company’s shares closed last Monday at $73.43.

According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 10.5% and a 46.3% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Treace Medical Concepts, and Organogenesis Holdings.

Currently, the analyst consensus on Alcon is a Moderate Buy with an average price target of $84.71, which is a 16.5% upside from current levels. In a report issued on May 12, Credit Suisse also initiated coverage with a Buy rating on the stock with a $96.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BSX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed